Managing Patients With High-Risk PDR and DME
Ehsan Rahimy, MD, outlines strategies for managing cases of high-risk PDR and DME, exploring new therapies and synergistic combinations with anti-VEGF and steroids for longer-lasting responses.
Stay updated with breaking news from Ehsan Rahimy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Ehsan Rahimy, MD, outlines strategies for managing cases of high-risk PDR and DME, exploring new therapies and synergistic combinations with anti-VEGF and steroids for longer-lasting responses.
Ehsan Rahimy, MD, discusses challenges in managing longstanding nAMD patients rotating through anti-VEGF treatments, highlighting the promise of newer therapies like aflibercept 8mg and faricimab.
An expert retina specialist discusses challenges faced by DME patients showing suboptimal response to standard anti-VEGF treatment, emphasizing the need to reduce injection burden while preventing vision loss.
Experts discuss the recent PULSAR and PHOTON studies with high dose aflibercept (8mg) and how they educate patients about this treatment approach.
Experts discuss insurer mandated step therapy and how to navigate treatment options for patients with diabetic macular edema (DME).